SCHEMBL7464533

SCHEMBL7464533

CN[C@H]1CC[C@H](N(C)C(=O)OC(C)(C)C)CC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.40
ASGR1 P07306 1/20 0.34
BTK Q06187 1/20 0.33
KAT6A Q92794 1/20 0.32
KAT8 Q9H7Z6 1/20 0.32
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
JAK3 P52333 1/20 0.32
GAA P10253 1/20 0.32
KDM4D Q6B0I6 1/20 0.32
BUB1 O43683 1/20 0.32
EPHX1 P07099 2/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CTSK P43235 2/20 0.31
PDE10A Q9Y233 1/20 0.30
PIK3CD O00329 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26667530 1.00 HSD11B1 (0.40) HSD11B1ASGR1BTKKAT6AKAT8
Hydrochloric Acid SCHEMBL8184993 0.98 HSD11B1 (0.40) HSD11B1ASGR1BTKKAT6AKAT8
Hydrochloric Acid SCHEMBL7419816 0.98 HSD11B1 (0.40) HSD11B1ASGR1BTKKAT6AKAT8
SCHEMBL190837 0.88 HSD11B1 (0.47) HSD11B1ASGR1KAT6AKAT8JAK2
SCHEMBL19624672 0.87 HSD11B1 (0.39) HSD11B1ASGR1BTKKAT6AKAT8
SCHEMBL5270126 0.83 HSD11B1 (0.41) HSD11B1ASGR1BTKKAT6AKAT8
SCHEMBL28804053 0.82 HSD11B1 (0.44) HSD11B1ASGR1KAT6AKAT8JAK2
SCHEMBL28804055 0.82 HSD11B1 (0.44) HSD11B1ASGR1KAT6AKAT8JAK2
SCHEMBL228179 0.82 HSD11B1 (0.46) HSD11B1ASGR1BTKGAAKDM4D
SCHEMBL23842059 0.81 HSD11B1 (0.43) HSD11B1ASGR1KAT6AKAT8JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 US disclosed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 US disclosed
US-20210369710-A1 MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN NALO THERAPEUTICS (US) 2021-12-02 US disclosed
US-6211228-B1 COMPOUNDS WITH AMINO, GUANIDINO AND AMIDINO HETEROCYCLIC COMPOUNDS AXYS PHARMACEUTICALS, INC 2001-04-03 US disclosed
US-6022969-A Compositions and methods for treating mast-cell mediated conditions AXYS PHARMACEUTICALS, INC. (US) 2000-02-08 US disclosed
EP-0782571-A1 COMPOSITIONS AND METHODS FOR TREATING MAST-CELL INFLAMMATORY CONDITION ARRIS PHARMACEUTICAL CORPORATION (US) 1997-07-09 EP disclosed
WO-1996009297-A1 COMPOSITIONS AND METHODS FOR TREATING MAST-CELL INFLAMMATORY CONDITION ARRIS PHARMACEUTICAL CORPORATION (US) 1996-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS SREBF1, SREBF2, NR1H3 HSD11B1 17/4885ASGR1 578/4885BTK 4740/4885
US-20210369710-A1 MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN MYC, MYCBP, MYCBP2 HSD11B1 4278/4885ASGR1 4011/4885BTK 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.